Yeji

$CGEM

Cullinan Therapeutics, Inc.

Runway:23 mo
NasdaqMarket cap: —CIK 0001789972

Upcoming catalysts

1 surfaced
NDA/BLA filedDate TBD
$CGEMCullinan Therapeutics, Inc.
CLN-049 · Relapsed/Refractory Acute Myeloid Leukemia (AML)
“In December 2025, CLN-049 received Fast Track designation for the treatment of relapsed/refractory acute myeloid leukemia ("AML") from the United States Food and Drug Administration”

Drug pipeline

CLN-081
Non Small Cell Lung Cancer
VK-2019
Nasopharyngeal Carcinoma
CLN-049
Relapsed/Refractory Acute Myeloid Leukemia (AML)
CLN-617
Advanced Solid Tumor
CLN-978
Rheumatoid Arthritis (RA
CLN-619
Multiple Myeloma

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06035744CLN-617Phase 1Recruiting2028-06-01
NCT07041099CLN-978Phase 1Recruiting2028-03-15
NCT06994143CLN-978Phase 1Recruiting2027-12-30
NCT05143996CLN-049Phase 1Recruiting2027-01-01
NCT06613360CLN-978Phase 1Recruiting2026-12-01
NCT05879744CLN-978Phase 1Active Not Recruiting2026-11-01
NCT06381141CLN-619Phase 1Active Not Recruiting2026-09-01
NCT05117476CLN-619Phase 1Active Not Recruiting2026-03-01
NCT04036682CLN-081Phase 2Active Not Recruiting2026-01-31
NCT03682055VK-2019Phase 2Terminated2020-06-23